We are a game changer
Your competitive advantage
Connect with a research powerhouse
MU offers a rare blend of expertise and resources, including medicine, veterinary medicine, agriculture and engineering on the same campus along with the most powerful university research reactor in America. Our NextGen Precision Health initiative, which unites private partners with MU’s network of hospitals, clinics and extension programs, is poised to accelerate medical breakthroughs for patients in Missouri and beyond.
Let's Work Together
We can help you turn your ideas into reality. Work with MU faculty consultants or partner with them on joint research projects.
License our innovations
With more than 100 new inventions every year, our portfolio of technologies is ready to be further developed for the marketplace, where research truly benefits society.
Access equipment & expertise
MU’s electron microscopy core research facility developed with Thermo Fischer Scientific and other advanced technology cores offer services and specialized equipment on a fee-for-service basis.
Incubate your business
Grow your business or invest in a new one located at the MU Life Science Business Incubator and numerous university research parks.
Develop your workforce
Gain a competitive edge by attracting talented MU interns and graduates.
Conduct clinical research
Hold your Phase I clinical trial at MU. Each year, we run hundreds of trials to test medical treatments for humans and animals.
Executive Director of Industry Partnerships and Engagement
More about our partners
"MU Health Care established a high level of ‘clinical agility’ that allowed us to jointly explore, implement and evaluate digital health products in iterative cycles. Collaborating with the experts at MU keeps our teams always close to the real-world needs and challenges of clinicians and patients."
FACTS & FIGURES
The MU Research Reactor has an exclusive agreement with Advanced Accelerator Applications International, SA (AAA), a Novartis company, to provide a key ingredient in a cancer therapy.
The FDA recently approved a pediatric clinical trial to test a new gene therapy developed by Decibel Therapeutics with MU patented technology to restore hearing.
The School of Medicine and Roche developed NAVIFY tumor board software to streamline crucial information and data for clinician teams providing personalized care to cancer patients.
MU increasingly relies on private philanthropy to provide the “margin of excellence,” including investment from corporate and foundation partners. Contact Mizzou Advancement’s Corporate Relations team to discuss your priorities and explore opportunities.